Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy

被引:10
|
作者
DeBernardo, RL
Perkins, RB
Littell, RD
Krasner, CN
Duska, LR
机构
[1] Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA
来源
OBSTETRICS AND GYNECOLOGY | 2005年 / 105卷 / 05期
关键词
D O I
10.1097/01.AOG.0000153026.61249.c7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To compare the efficacy of dalteparin, a low-molecular-weight heparin, to unfractionated heparin (UFH) in the prevention of deep venous thrombosis (DVT) and pulmonary embolism in patients after surgery for gynecologic malignancy. METHODS: The medical records of all patients undergoing major surgery on the Gynecologic Oncology Service at the Massachusetts General Hospital from July 2002 through April 2003 were reviewed. Patients with confirmed malignancy were included. Between July 1, 2002, and November 15, 2002, dalteparin (5,000 U subcutaneously each day) was used for postoperative prophylaxis for DVT and pulmonary embolus. After November 15, 2002, the method of prophylaxis was changed to UFH (5,000 U subcutaneously every 8 hours) exclusively. Patients were evaluated for DVT or pulmonary embolus based on clinical suspicion using computed tomographic angiography, ventilation and perfusion scan, or lower extremity doppler. RESULTS: A total of 214 patients were identified who met study criteria. Dalteparin was administered to 103 patients, and UFH was administered to 111. The rates of clinically significant DVT or pulmonary embolus in patients receiving dalteparin and UFH were 8.9% and 1.2%, respectively (P = .009). Major risk factors for DVT or pulmonary embolus, including age, obesity, duration of surgery, and type of malignancy, did not differ between groups. There were no significant differences in bleeding complications or transfusion requirements between groups. CONCLUSION: The low-molecular-weight heparin dalteparin dosed 5,000 U daily is inadequate postoperative prophylaxis in women undergoing surgery for gynecologic cancer. In addition, heparin administered every 8 hours was not associated with increased bleeding complications. The use of dalteparin at the doses used in this study should be questioned until a large randomized trial shows efficacy m these high-risk patients. (c) 2005 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:1006 / 1011
页数:6
相关论文
共 50 条
  • [1] Dalteparin: A low-molecular-weight heparin
    Howard, PA
    ANNALS OF PHARMACOTHERAPY, 1997, 31 (02) : 192 - 203
  • [3] Anticoagulation with low-molecular-weight heparin dalteparin in atrial fibrillation
    Bechtold, H
    Sawitzki, H
    Gunzenhauser, D
    Janssen, D
    EUROPEAN HEART JOURNAL, 2000, 21 : 8 - 8
  • [4] A retrospective comparison of oral rivaroxaban versus subcutaneous low-molecular-weight heparin for postoperative thromboprophylaxis in women with a gynecologic malignancy
    Nagy, A.
    Tegge, A. N.
    Borden, L. E.
    Osborne, J. L.
    Valea, F. A.
    Iglesias, D. A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 199 - 200
  • [5] Postoperative thromboprophylaxis with oral rivaroxaban versus subcutaneous low-molecular-weight heparin: a retrospective comparison in women with a gynecologic malignancy
    Swaroop, Meyha
    Borden, Lindsay
    Locklear, Tonja
    Armbruster, Shannon
    Saks, Erin
    Osborne, Janet
    Valea, Fidel
    Iglesias, David
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S239 - S239
  • [6] LOW-MOLECULAR-WEIGHT HEPARIN (FRAGMIN) PROPHYLAXIS IN GYNECOLOGIC SURGERY
    BRIEL, RC
    HERMANN, C
    DOLLER, P
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 119 - 119
  • [7] Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience
    Schinzel, H
    Berghoff, K
    Beuermann, I
    Sauer, O
    von Mach, MA
    Weilemann, LS
    TRANSFUSION, 2006, 46 (04) : 624 - 629
  • [8] A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin
    Gerdsen, Frank
    Luxembourg, Beate
    Langer, Florian
    Bauersachs, Rupert
    Lindhoff-Last, Edelgard
    BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (06) : 477 - 481
  • [9] Heparin and low-molecular-weight heparin
    Gray, Elaine
    Mulloy, Barbara
    Barrowcliffel, Trevor W.
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (05) : 807 - 818
  • [10] Low-molecular-weight heparin for thrombophilia in pregnant women
    Bar, J
    Cohen-Sacher, B
    Hod, M
    Blickstein, D
    Lahav, J
    Merlob, P
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2000, 69 (03) : 209 - 213